Digital biomarkers

Abstract

Currently, assessing the severity and progression of symptoms in a subject diagnosed with muscle dysfunction, in particular SMA, involves clinical monitoring and testing of the subject every 6 to 12 months. However, more frequent monitoring and testing of the subject is preferred, but increasing the frequency of clinical monitoring and testing may be expensive and not very convenient for the subject. Thus, as described herein, the severity and progression of symptoms are assessed via remote monitoring and testing of the subject outside the clinical environment, providing advantages in terms of cost, ease of monitoring, and convenience for the subject. Systems, methods, and devices according to the present disclosure provide a diagnostic for assessing distal hypomyotonia in a subject suffering from muscle dysfunction, particularly SMA, based on active testing of the subject.

Description

technical field [0001] The present invention relates to a medical device for improving subject testing and subject analysis. More specifically, aspects described herein provide a diagnostic device for assessing muscle disability, in particular the severity and progression of symptoms of spinal muscular atrophy (SMA) in a subject, by active testing on the subject, systems and methods. Background technique [0002] Spinal muscular atrophy (SMA) is an autosomal recessive genetic disease, also known as proximal spinal muscular atrophy and 5q type spinal muscular atrophy. It is a life-threatening neuromuscular disorder with low incidence associated with loss of motor neurons and progressive muscle wasting. [0003] SMA has become a health problem and a significant economic burden on the health system. As SMA is a clinically heterogeneous disease of the CNS, diagnostic tools are needed to reliably diagnose and identify current disease state and symptom progression, thereby faci...

AI Technical Summary

Problems solved by technology

While it would be ideal to monitor and test subjects more frequently, increasing the frequency of clinical monitoring and testing can be costly and inconvenient for subjects

Images